AllazoHealth’s AI Technology Benefits Patients with Rare Diseases

Medication Adherence Patient Engagement Patient Support Programs Predictive Analytics Rare Diseases

According to the National Institutes of Health, more than 30 million Americans are living with rare diseases, and it is estimated that there are 10,000 known rare diseases. Of those, only 7,000 have identified molecular causes, and only about 500 have approved treatments. The process from diagnosis to prognosis and treatment is a complex one for individuals who may suffer from diseases not even known to clinicians. 

Keeping patients engaged in their support programs is critical to ensuring therapy initiation, adherence, and positive outcomes. This is especially important for patients with rare diseases because their health outcomes and quality of life depend on starting and staying on therapy as prescribed. Patient education, shared decision-making, and patient outreach are key patient engagement strategies towards that end. Fortunately, AI has shown a meaningful impact on patient engagement through delivering personalized interventions at the individual level.

Improving the Rare Disease Patient Experience with Identified Patient Data

Our case studies have shown a 5.5x greater adherence uplift compared to traditional programs, a 13.3 percent increase in days on therapy, and 23 percent reduction in intervention costs. This is all achieved through AllazoHealth’s AI technology, which uses up to 500 data predictors about an individual to anticipate how they are engaging with their treatment and how to best support them.

The numbers address one of the biggest barriers to pharmaceutical companies developing programs for patients with rare diseases – the small sample size of the patient population. While their care navigator or nurse in the patient support program may know each patient well, they cannot orchestrate the entire patient experience for each and every individual. Developing interventions for this population requires a greater degree of personalization, coordination, and scalability. All of which are functions of an advanced AI platform. 

Supporting Patients With Rare Diseases Requires the Right AI Tool

Patients with rare diseases don’t always get the support they need and deserve, but drug manufacturers can change that with the right approach. (Read our article, 5 Ways Pharma Can Support Patients with Rare Diseases.) Often, patients with rare diseases experience a gap in therapy based on their unique circumstances. Predictive analytics and AI can help identify these patients and pharmaceutical companies address these gaps by anticipating their behaviors and tailoring interventions to drive their next-best-action toward initiating or adhering to therapy. For patients who have not had access to or even the option of receiving support for their condition, programs powered by AI offer a great amount of relief because of the highly tailored experience.

With the use of AllazoHealth’s AI technology, pharma companies can continue to build their support programs for patients living with rare diseases and scale the personalized experience to help patients thrive despite their conditions.